NewAmsterdam Pharma to Present Data on Obicetrapib at AHA Scientific Sessions
NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) —
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN study evaluating obicetrapib in patients with Heterozygous Familial Hypercholesterolemia in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions.
The AHA Scientific Sessions are taking place November 16 – 18, 2024 in Chicago, Illinois. In addition to the presentation at the AHA conference, NewAmsterdam management will also be participating in the Jefferies London Healthcare Conference from November 19 – 21, 2024 in London.
Impact on Individuals:
The presentation of additional data on obicetrapib at the AHA Scientific Sessions can have a significant impact on individuals at risk of cardiovascular disease with elevated LDL-C levels. The data presented may provide insights into the safety and efficacy of this new treatment option, potentially offering hope for those who have not found existing therapies to be effective or well-tolerated.
Global Impact:
The participation of NewAmsterdam Pharma in prestigious healthcare conferences such as the AHA Scientific Sessions and Jefferies London Healthcare Conference highlights the company’s commitment to advancing research and development in the field of cardiovascular disease. The data presented at these conferences may have far-reaching implications for the global healthcare community, potentially leading to new treatment options for patients worldwide.
Conclusion
In conclusion, NewAmsterdam Pharma’s upcoming presentations at the AHA Scientific Sessions and Jefferies London Healthcare Conference are eagerly anticipated events in the medical community. The data to be presented has the potential to impact individuals at risk of cardiovascular disease as well as the global healthcare landscape. We look forward to the insights and advancements that may result from these presentations.
